Teleflex has received the US Food and Drug Administration (FDA) 510(k) market clearance for ArrowEvolution PICC with Chlorag+ard technology.
The launch of ArrowEvolution PICC with Chlorag+ard technology in the US is expected in the fourth quarter of 2010.
ArrowEvolution is a peripherally inserted central catheter with a Chlorhexedine-based solution that has been chemically-bonded into the surface of the catheter both intra- and extralumenally.
Teleflex claims that the Arrow brand vascular access technology helps in attaining zero central line-associated bloodstream infections.
Teleflex chairman and chief executive officer Jeff Black said that the market clearance from FDA for the ArrowEvolution PICC with Chlorag+ard technology represents another significant milestone for Teleflex as they continue to provide innovative technologies to support healthcare providers who are working to improve patient outcomes through infection prevention.
“We believe the ArrowEvolutionPICC with its anti-microbial coating will provide a technological advancement and unique option to clinicians in their efforts to protect against central line-associated bloodstream infections, a major contributor to hospital acquired infections,” Black said.